ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "ANCA associated vasculitis"

  • Abstract Number: 0722 • ACR Convergence 2025

    Estimating two-year risk of relapse in individuals with ANCA-associated vasculitis in a randomized controlled trial of plasma exchange and glucocorticoids

    Mats Junek1, Quazi Ibrahim2, Peter Merkel3, Eswari Vilayur4, Ron Wald5, Todd Fairhead6, David Massicotte-Azarniouch6, Louis Girard7, Christian Pagnoux8, Nader Khalidi2, David Jayne9 and Michael Walsh2, 1St Joseph's Healthcare Hamilton, Hamilton, ON, Canada, 2McMaster University, Hamilton, ON, Canada, 3University of Pennsylvania, Philadelphia, PA, 4John Hunter Hospital, Newcastle, New South Wales, Australia, 5St Michael's Hospital, Toronto, ON, Canada, 6University of Ottawa, Ottawa, ON, Canada, 7University of Calgary, Calgary, AB, Canada, 8Mount Sinai Hospital, Toronto, ON, Canada, 9University of Cambridge, Cambridge, United Kingdom

    Background/Purpose: People with anti-neutrophil cytoplasm antibody (ANCA) associated vasculitis (AAV) vary in their risk of a relapse of disease. Estimating an individual’s risk may inform…
  • Abstract Number: 0726 • ACR Convergence 2025

    Real-World Avacopan Use in Granulomatosis with Polyangiitis and Microscopic Polyangiitis: Insights from United States Claims Data on Outcomes and Adherence

    Sebastian E Sattui1, Elizabeth Ibiloye2, Niranjan Kathe3, Sam Oh4, Virginia Noxon-Wood5, Iman Mohammadi5, Laura Moore-Schiltz5 and Tingting Li6, 1Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, 2Amgen Inc, Thousand Oaks, CA, 3Amgen Inc, San Diego, CA, 4Amgen Inc, South San Francisco, CA, 5Inovalon, Bowie, MD, 6Washington University School of Medicine, St. Louis

    Background/Purpose: Granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) are the most common types of anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV). Treatment-related toxicities, particularly from glucocorticoid…
  • Abstract Number: 2521 • ACR Convergence 2025

    DANGER Score as Predictor of Mortality in ANCA-Associated Vasculitis with or without Glomerulonephritis: Data from the Almenara Vasculitis Cohort

    Victor Pimentel-Quiroz1, Alvaro Oyarce-Calderón2, Allison Figueroa-Sánchez3, Leonor León-Yaurimucha3, Rocío Gamboa-Cárdenas4, Zoila Rodríguez-Bellido5, Risto Perich-Campos6, Graciela Alarcón7 and Manuel Ugarte-Gil8, 1Universidad Científica del Sur, San Isidro, Peru, 2Hospital Nacional Guillermo Almenara Irigoyen, San Miguel, Peru, 3Universidad Científica del Sur, Lima, Peru, 4Universidad Científica del Sur, Lima, Peru, 5Hospital Nacional Guillermo Almenara Irigoyen; Universidad Nacional Mayor de San Marcos, Lima, Peru, 6Hospital Nacional Guillermo Almenara Irigoyen; Universidad Nacional Mayor de San Marcos, La Molina, Peru, 7The University of Alabama at Birmingham, Oakland, CA, 8Universidad Cientifica del Sur, Lima, Peru

    Background/Purpose: The DANGER score can predict mortality in patients with ANCA-associated vasculitis (AAV) with glomerulonephritis (GN). However, this score has not been widely validated and,…
  • Abstract Number: 2452 • ACR Convergence 2025

    Preliminary Safety, Efficacy, and Cellular Kinetics of CTA311, a CD19 Targeted Universal CAR-T Therapy, for Active Autoimmune Diseases

    Sanbin Wang1, Heng Mei2, Dongmei Zhou3, Wei Xie2, Songlou Yin3, Chunmei Liu3, Hanwei Wang4, Huan Zhou5, Yue Xie6, Lu Han7, Jiangtao Ren8, Yali Zhou8, Wengang Ge7 and Jan Davidson-Moncada8, 1920th Hospital of Joint Logistic Support Force, Kunming, China (People's Republic), 2Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China (People's Republic), 3The Affiliated Hospital of Xuzhou Medical University, Xuzhou, China (People's Republic), 4The Third People’s Hospital of Bengbu, Beng bu, China (People's Republic), 5Clinical Research Hospital of the First Affiliated Hospital of Anhui Medical University, Hefei, China (People's Republic), 6Bioheng Therapeutics Limited, Nan Jing Shi, China (People's Republic), 7Bioheng Therapeutics Co., Limited, Nanjing, China (People's Republic), 8Bioheng Therapeutics Co., Limited, Nan Jing, China (People's Republic)

    Background/Purpose: Systemic lupus erythematosus (SLE) and anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) are autoimmune conditions characterized by B cell activation, autoreactivity, and autoantibody production. CAR-T therapy…
  • Abstract Number: 1603 • ACR Convergence 2025

    SGLT-2 Inhibitors are Associated with Lower Risk of End Stage Renal Disease (ESRD) and Lower Mortality in ANCA-associated Vasculitis With Kidney Involvement

    Julia Foos1, Naveed Shah2 and Nezam Altorok3, 1Unversity of Toledo College of Medicine and Life Sciences, Toledo, 2University of Toledo College of Medicine and Life Sciences, Toledo, 3The University of Toledo, Toledo, OH

    Background/Purpose: ANCA-associated vasculitis encompasses three main conditions: Granulomatosis with Polyangiitis (GPA, previously called Wegener’s granulomatosis), Eosinophilic Granulomatosis with Polyangiitis (EGPA, previously called Churg-Strauss), and microscopic…
  • Abstract Number: 0721 • ACR Convergence 2025

    Pulmonary Manifestations of Granulomatosis with Polyangiitis and Microscopic Polyangiitis

    Mats Junek1, Sara Choi2, Stephanie Garner3, Saara Rawn4, David Cuthbertson5, Curry Koening6, Carol Langford7, Carol McAlear8, Paul Monach9, Larry Moreland10, Christian Pagnoux11, Philip Seo12, Ulrich Specks13, Kenneth Warrington13, Gerard Cox1, Nader Khalidi14 and Peter Merkel8, 1St Joseph's Healthcare Hamilton, Hamilton, ON, Canada, 2Queen's University, Kingston, ON, Canada, 3University of Calgary, Calgary, AB, Canada, 4NOSM School of Medicine, Sudbury, ON, Canada, 5University of South Florida, Tampa, 6University of Texas Dell Medical School, Austin, TX, 7Cleveland Clinic, Moreland Hills, OH, 8University of Pennsylvania, Philadelphia, PA, 9VA Boston Healthcare System, Boston, MA, 10University of Colorado, Denver, CO, 11Mount Sinai Hospital, Toronto, ON, Canada, 12Johns Hopkins University, Baltimore, MD, 13Mayo Clinic, Rochester, MN, 14McMaster University, Hamilton, ON, Canada

    Background/Purpose: There is limited knowledge of the epidemiology and complications of pulmonary manifestations in ANCA-associated vasculitis (AAV). This analysis focused describing the range of pulmonary…
  • Abstract Number: 0724 • ACR Convergence 2025

    Risk of Drug Induced Liver Injury with Use of Avacopan in ANCA Vasculitis – Results from Real-World Data

    Milad Heydari-Kamjani1, Elleson Harper2 and Haseeb Chaudhary3, 1University Hospitals Cleveland Medical Center/ Case Western Reserve University, Cleveland, OH, 2University Hospitals Cleveland Medical Center/Case Western Reserve University, Cleveland, OH, 3Case Western Reserve University, Westlake, OH

    Background/Purpose: Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a systemic autoimmune vasculitis. Avacopan, a novel oral C5a receptor inhibitor, has emerged as an adjunct therapy…
  • Abstract Number: 2519 • ACR Convergence 2025

    A Disproportionality Analysis of FDA Adverse Event Reporting System (FAERS) Events for Avacopan

    Shiamak Cooper1, Asim Khanfar2, Yousef al-mabrouk3, Omar Hamdan4 and Anthony Ocon5, 1Rochester General Hospital, Irondequoit, NY, 2Rochester General Hospital, Rochester, NY, 3Prince Hanza Hospital, Amman, Jordan, 4University of Jordan, Az-Zarqa, Jordan, 5Rochester Regional Health, Fairport, NY

    Background/Purpose: Avacopan, a C5a receptor inhibitor, is used as an adjunctive treatment for ANCA-associated vasculitis. Previous studies have highlighted its efficacy in reducing glucocorticoid use…
  • Abstract Number: 2144 • ACR Convergence 2025

    The Association Between Age at Diagnosis and Health-Related Quality of Life in ANCA-Associated Vasculitis

    Jessica Bloom1, Kaci Pickett-Nairne2, Lori Silveira1, Cristina Burroughs3, Katrina Bargender4, Amy Bolton4, Christine Yeung4, Jennifer Gordon5, Peter Merkel6 and Karen James7, 1University of Colorado, Aurora, CO, 2University of Colorado, Denver, 3University of South Florida, Tampa, FL, 4Vasculitis Patient-Powered Research Network, Philadelphia, PA, 5Vasculitis Foundation, Kansas City, MO, 6University of Pennsylvania, Philadelphia, PA, 7University of Utah, Salt Lake City, UT

    Background/Purpose: ANCA-associated vasculitis (AAV) is a chronic autoimmune condition that significantly impacts patients’ quality of life. It is unknown whether this impact varies based on…
  • Abstract Number: 1604 • ACR Convergence 2025

    Impact and risk factors of anti-rituximab antibodies in small-vessel vasculitis: a multicenter retrospective study

    Lucas Khellaf1, Raphaele Seror2, caterina ricordi3, stephanie chhun4, audes gleizes4, hervé lobbes5, clara pouchelon6, marie Charlotte Besse7, Jean-Emmanuel Kahn8, sabine revuz9, Marina Cumin10, Dimitri Titeca-Beauport11, Matthias Papo6, Philippe Rémy6, marie Desprets12, florian garo13, Charles Ronsin14, Salima Hacein-Bey-Abina6, Amélie Servettaz15, Cacoub Patrice16, Xavier Puéchal17 and Benjamin Terrier18, 1AP-HP, Paris, 2Department of Rheumatology, National referral center for auto immune disease and Sjogren disease, Université Paris-Saclay, INSERM UMR1184: Centre for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Le Kremlin Bicêtre, Paris, France., le kremlin bicetre, France, 3Unit of Rheumatology, Azienda USL - IRCCS di Reggio Emilia, and University of Modena and Reggio Emilia, Reggio Emilia, Italy, 4APHP, Paris, Ile-de-France, France, 5Department of Internal Medicine, Hôpital Estaing, Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand, France, 6APHP, Paris, France, 7CHU Tours, Tours, France, 8Ambroise Paré hospital, Boulogne, France, 9CHU de la Réunion, Réunion, France, 10Centre hospitalier de Libourne, Libourne, France, 11CHU Amiens, Amiens, France, 12CH Chôlet, Cholet, France, 13CHU Nîmes, Nîmes, France, 14CHU Nantes, Nantes, France, 15Internal Medicine, CHU Reims, Reims, France, 16Department of Internal Medicine and Clinical Immunology, Sorbonne Universités, AP-HP, Groupe Hospitalier Pitié-Salpêtrière, Centre national de références Maladies Autoimmunes et systémiques rares, Centre national de références Maladies Autoinflammatoires rares et Amylose inflammatoire (CEREMAIA), INSERM, UMR S959, Immunology-Immunopathology-Immunotherapy (I3), Paris, France, Paris, France, 17Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hospital Cochin, and Université Paris Cité, Paris ( 75014 ), Ile-de-France, France, 18Cochin Hospital, Paris, France

    Background/Purpose: Small vessel vasculitis mainly includes ANCA-associated vasculitis (AAV) and cryoglobulinemic vasculitis (CV), leading to significant organ damage. Rituximab (RTX), an anti-CD20 monoclonal antibody, has…
  • Abstract Number: 0720 • ACR Convergence 2025

    Current State of Racial, Ethnic, Sex, and Geographical Diversity in ANCA-associated vasculitis and Giant Cell Arteritis Trials

    Manuel Carpio Tumba1, Aida Mohamadi2, Diana Louden3, Victor Pimentel-Quiroz4, Michael Putman5, Didem Saygin6, Raisa Lomanto Silva7 and Sebastian E Sattui8, 1University of Pittsburgh, Pittsburgh, PA, 2Tehran University of Medical Sciences, Tehran, Iran, 3University of Washington, Seattle, WA, 4Universidad Científica del Sur, San Isidro, Peru, 5The Medical College of Wisconsin, Milwaukee, WI, 6Rush University Medical Center, Chicago, IL, 7Massachusetts General Hospital, Boston, MA, 8Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA

    Background/Purpose: Randomized controlled trials (RCTs) generate unbiased efficacy estimates and are required for regulatory approval. Understanding the degree to which they include racial, ethnic, sex,…
  • Abstract Number: 0725 • ACR Convergence 2025

    Sinonasal Symptom Profiles Associated with Disease Activity in an International Cohort of Patients with ANCA-Associated Vasculitis

    Rennie Rhee1, Christine Yeung2, Darrin White3, Mary Gibson3, Jessica Nguyen4, Cristina Burroughs5, Jennifer Gordon6, Noam A. Cohen4, Jeffrey Morris4 and Peter Merkel1, 1University of Pennsylvania, Philadelphia, PA, 2Vasculitis Patient-Powered Research Network, Philadelphia, PA, 32. Patient Research Partner, Vasculitis Patient-Powered Research Network, Philadelphia, 4University of Pennsylvania, Philadelphia, 5University of South Florida, Tampa, FL, 6Vasculitis Foundation, Kansas City, MO

    Background/Purpose: Sinus and nasal symptoms are common and associated with a higher risk of relapse in patients with ANCA-associated vasculitis (AAV). Previously, our group found…
  • Abstract Number: 0717 • ACR Convergence 2024

    Associations Between Calendar Time and Age at Diagnosis with Mortality in a National Cohort of Veterans with ANCA-Associated Vasculitis from 2001-2020

    Jennifer Hanberg1, Svetlana Eden2, Amy Anderson-Mellies2, Suman Kundu2, Matthew Freiberg2, Zachary Wallace3 and Evelyn Hsieh4, and the Veterans Aging Cohort Study Project Team, 1Brigham and Women's Hospital, Boston, MA, 2Vanderbilt University Medical Center and Tennessee Valley VA, Nashville, TN, 3Massachusetts General Hospital, Newton, MA, 4Yale School of Medicine / VA Connecticut Healthcare System, West Haven, Connecticut, New Haven, CT

    Background/Purpose: It is not clear whether advances in ANCA-associated vasculitis (AAV) management between 2001-2020 have translated to improvement in population-level outcomes, including among older adults.…
  • Abstract Number: 0824 • ACR Convergence 2024

    The Effect of Intranasal Niclosamide on Nasal Symptoms in Patients with ENT Manifestations of ANCA-Associated Vasculitis (AAV): Post Hoc Analysis of Subset of Patients Recruited to the PROTECT-V Trial

    Benjamin Lim1, Wendi Qian1, Francis Dowling2, Michael Chen-Xu1, Alan Salama3 and Rona Smith4, 1University of Cambridge, Cambridge, 2Cambridge University Hospitals NHS Foundation Trust, Cambridge, 3University College London, London, 4University of Cambridge, Cambridge, United Kingdom

    Background/Purpose: Ear, nose and throat (ENT) manifestations are common in ANCA associated vasculitis (AAV), particularly the PR3 (proteinase 3) sub type.  There is unmet need…
  • Abstract Number: 1603 • ACR Convergence 2024

    Antineutrophil Cytoplasmic Autoantibody Levels in Patients in the Avacopan Phase 3 Trial

    Frank B. Cortazar1, Duvuru Geetha2, Salem Almaani3, Christina Song4, Tomasz M. Wilmanski4, Alana M. Bozeman4, Peter Merkel5 and David Jayne6, and ADVOCATE Study Group, 1New York Nephrology Vasculitis and Glomerular Center, Saint Peter’s Hospital-Albany, Albany, NY, 2Johns Hopkins University, Baltimore, MD, 3The Ohio State University Medical Center, Columbus, OH, 4Amgen Inc., Thousand Oaks, CA, 5University of Pennsylvania, Philadelphia, PA, 6University of Cambridge, Cambridge, United Kingdom

    Background/Purpose: The utility of measuring serial antineutrophil cytoplasmic autoantibody (ANCA) levels to guide treatment in granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) is controversial.…
  • « Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • …
  • 23
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology